Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nomegestrol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR known ✓ | P06401 | 5/20 | 0.72 |
| ▸ | LMNA | P02545 | 5/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.80 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.80 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.80 |
| ▸ | NR3C1 | P04150 | 5/20 | 0.72 |
| ▸ | AR | P10275 | 4/20 | 0.72 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.72 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | SHBG | P04278 | 1/20 | 0.51 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.51 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.51 |
| ▸ | BLM | P54132 | 1/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nomegestrol SCHEMBL19760878 | 1.00 | LMNA (0.80) | LMNACYP3A4CYP2C9CYP2C19PGR | |
| Nomegestrol SCHEMBL6415665 | 0.99 | LMNA (0.79) | LMNACYP3A4CYP2C9CYP2C19PGR | |
| Nomegestrol SCHEMBL37518 | 0.98 | LMNA (0.77) | LMNACYP3A4CYP2C9CYP2C19PGR | |
| Nomegestrol SCHEMBL27486762 | 0.95 | LMNA (0.76) | LMNACYP3A4CYP2C9CYP2C19PGR | |
| Nomegestrol SCHEMBL4913845 | 0.93 | LMNA (0.74) | LMNACYP3A4CYP2C9CYP2C19PGR | |
| SCHEMBL9322389 | 0.89 | LMNA (0.82) | LMNACYP3A4CYP2C9CYP2C19PGR | |
| SCHEMBL141181 | 0.88 | CYP2C19 (0.64) | LMNACYP3A4CYP2C9CYP2C19PGR | |
| Acetic Acid SCHEMBL282894 | 0.87 | CYP2C19 (0.62) | LMNACYP3A4CYP2C9CYP2C19PGR | |
| Nomegestrol Acetate SCHEMBL37517 | 0.84 | PGR (1.00) | LMNACYP3A4CYP2C9CYP2C19PGR | |
| Nomegestrol Acetate SCHEMBL8817628 | 0.84 | PGR (1.00) | LMNACYP3A4CYP2C9CYP2C19PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1709 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4440706-B1 | COMPOSITIONS FOR PROMOTING HAIR GROWTH | ESTETRA SRL (BE) | 2026-04-29 | — | — | EP | claimed |
| US-20260090995-A1 | ORODISPERSIBLE DOSAGE UNIT CONTAINING AN ESTETROL COMPONENT | ESTETRA SRL (BE) | 2026-04-02 | — | — | US | claimed |
| EP-4637777-A1 | USE OF ESTETROL IN HEPATICALLY IMPAIRED PATIENTS | Estetra SRL (BE) | 2025-10-29 | — | — | EP | claimed |
| US-12427114-B2 | Orodispersible dosage unit containing an estetrol component | ESTETRA SRL (BE) | 2025-09-30 | — | — | US | claimed |
| US-20250255968-A1 | INTRAVAGINAL DEVICES FOR DRUG DELIVERY | KISER PATRICK F (US) | 2025-08-14 | — | — | US | claimed |
| US-20250230989-A1 | HEAT PIPE INTEGRATED WITHIN A FASTENER | RAJAGOPAL BALACHANDRAN (IN) | 2025-07-17 | — | — | US | claimed |
| US-20250195450-A1 | BIOERODIBLE DRUG DELIVERY IMPLANTS | HERA HEALTH SOLUTIONS INC. | 2025-06-19 | — | — | US | claimed |
| US-12318395-B2 | Ethinyl estradiol-β-cyclodextrin complex and process for preparing thereof | LABORATORIOS LEON FARMA, S.A. (ES) | 2025-06-03 | — | — | US | claimed |
| US-20250099485-A1 | COMPOSITIONS FOR PROMOTING HAIR GROWTH | ESTETRA SRL (BE) | 2025-03-27 | — | — | US | claimed |
| EP-4440706-A1 | COMPOSITIONS FOR PROMOTING HAIR GROWTH | Estetra SRL (BE) | 2024-10-09 | — | — | EP | claimed |
| EP-0956022-A1 | HORMONAL COMPOSITION CONSISTING OF AN OESTROGEN COMPOUND AND OF A PROGESTATIONAL COMPOUND | LABORATOIRE THERAMEX (MC) | 1999-11-17 | — | — | EP | claimed |
| WO-1999048477-A1 | TOPICAL HORMONAL COMPOSITION WITH SYSTEMIC EFFECT | LABORATOIRE THERAMEX (MC) | 1999-09-30 | — | — | WO | claimed |
| WO-1998015279-A1 | HORMONAL COMPOSITION CONSISTING OF AN OESTROGEN COMPOUND AND OF A PROGESTATIONAL COMPOUND | LABORATOIRE THERAMEX (MC) | 1998-04-16 | — | — | WO | claimed |
| EP-0783310-A1 | NOVEL HORMONAL MEDICAMENTS AND USE THEREOF FOR CORRECTING OESTROGEN DEFICIENCIES | LABORATOIRE THERAMEX S.A. (MC) | 1997-07-16 | — | — | EP | claimed |
| WO-1997004784-A1 | NOVEL HORMONAL MEDICAMENTS AND USE THEREOF FOR CORRECTING OESTROGEN DEFICIENCIES | LABORATOIRE THERAMEX (MC) | 1997-02-13 | — | — | WO | claimed |
| EP-0510167-B1 | NOVEL STEROIDAL ORGANIC SUBSTANCE CRYSTALLIZATION METHOD AND COMPOUNDS THEREBY OBTAINED | THERAMEX (MC) | 1995-08-23 | — | — | EP | claimed |
| US-5266712-A | Process for crystallizing the organic substances from steroidal origin and the thus obtained compounds | LABORATOIRE THERAMEX S.A. (MC) | 1993-11-30 | — | — | US | claimed |
| EP-0510167-A1 | NOVEL STEROIDAL ORGANIC SUBSTANCE CRYSTALLIZATION METHOD AND COMPOUNDS THEREBY OBTAINED. | THERAMEX (MC) | 1992-10-28 | — | — | EP | claimed |
| WO-1992008730-A1 | NOVEL STEROIDAL ORGANIC SUBSTANCE CRYSTALLIZATION METHOD AND COMPOUNDS THEREBY OBTAINED | LABORATOIRE THERAMEX S.A. (MC) | 1992-05-29 | — | — | WO | claimed |
| US-4544555-A | LUTEAL DEFICIENCY HYPERESTROGNIA, HYPERANDROGENIA, SEBORRHEA AND/O | GASTAUD JEAN M | 1985-10-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260090995-A1 | ORODISPERSIBLE DOSAGE UNIT CONTAINING AN ESTETROL COMPONENT | HSD17B11, CYP17A1, SRD5A2 | PGR 21/4885LMNA 3212/4885CYP3A4 47/4885 |
| US-20250099485-A1 | COMPOSITIONS FOR PROMOTING HAIR GROWTH | FGF1, HDGF, NGF | PGR 1857/4885LMNA 2652/4885CYP3A4 4572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.